Suramin in Treating Patients With Recurrent Primary Brain Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients with recurrent primary brain tumors following radiation therapy.
|Brain and Central Nervous System Tumors||Drug: chemotherapy Drug: suramin||Phase 2|
|Study Design:||Primary Purpose: Treatment|
|Official Title:||ANALYSIS OF THE EFFICACY OF SURAMIN IN RECURRENT MALIGNANT PRIMARY BRAIN TUMORS|
|Study Start Date:||July 1995|
|Study Completion Date:||May 2004|
OBJECTIVES: I. Estimate the efficacy of suramin in patients with recurrent primary brain tumors as measured by radiographic response, time to progression, and survival. II. Assess the toxic effects of suramin in this patient population.
OUTLINE: Single-Agent Chemotherapy. Suramin, SUR, NSC-34936.
PROJECTED ACCRUAL: If at least 1 of the first 14 patients experiences at least a partial response, a total of 25 patients will be entered over approximately 30 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002639
|United States, Georgia|
|Department of Neurosurgery - Emory|
|Atlanta, Georgia, United States, 30322|
|Study Chair:||Jeffrey J. Olson, MD||Emory University|